Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Bucheon-si
Clinical trial register · South Korea

Clinical Trials in Bucheon-si, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3365 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:17 UTC
3365
Studies in scope
all four open statuses
1831
Recruiting now
open to new participants
500
Lead sponsors
across recruiting studies
Top sites
Seoul 2821 Daegu 554 Seongnam-si 493 Busan 468 Goyang-si 396
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Seung-Jung Park9 AstraZeneca6 Boehringer Ingelheim5 Jaseng Medical Foundation5 AbbVie5
Site location
Seoul2821 Daegu554 Seongnam-si493 Busan468 Goyang-si396
All 252 locations
Target enrolment
to

Trials with a site in Bucheon-si

112 of 3365 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Not yet open
Bristol-Myers Squibb
Phase 3
2,380
Ulsan, Goyang-si, Namdong-gu, Busan, Seoul, Bucheon-si, Goyang, Iksan
2026-12-16
Not yet open
Novo Nordisk A/S
Phase 3
8,500
Bucheon-si, Seongnam-si, Suwon, Uijeongbu-si, Yangsan, Busan, Daegu, Daejeon
2026-10-26
Not yet open
PULSTA TPV Observational Study
NCT07747207Heart Disease
Taewoong Medical Co., Ltd.
Observational
200
Bucheon-si, Seoul
2026-10
Not yet open
Chonnam National University Hospital
Not applicable
1,252
Bucheon-si, Changwon, Cheonan, Cheongju-si, Chuncheon, Daegu, Daejeon, Gwangju
2026-09-01
Not yet open
Eli Lilly and Company
Phase 3
170
Bucheon-si, Deagu, Junggu, Seongnam, Seoul
2026-09
Recruiting
AstraZeneca
Phase 3
2,500
Anyang, Bucheon-si, Daegu, Seoul, Yangsan
2026-08-19
Recruiting
AstraZeneca
Phase 3
600
Bucheon-si, Gyeonggi-do, Jongno-gu, Junggu, Seoul
2026-07-08
Not yet open
Seoul National University Hospital
Not applicable
2,301
Chuncheon, Gangneung, Anyang-si, Bucheon-si, Goyang-si, Changwon, Busan, Daegu
2026-06-15
Recruiting
Dompé Farmaceutici S.p.A
Phase 3
150
Wŏnju, Gwangju, Bucheon-si, Seoul
2026-06-02
Recruiting
Safety and Effectiveness of Ultrasound-guided Pharmacopuncture for Spinal Diseases
NCT07543692Spinal Disease, Neck Pain, Low Back Pain, Radiculopathy
Jaseng Medical Foundation
Observational
600
Daejeon, Seoul, Bucheon-si, Yangsan
2026-04-29
Recruiting
The DECISION-CTO Extended 10 Y Follow-up
NCT06908499Coronary Artery Disease
Seung-Jung Park
Observational
840
Anyang, Bucheon-si, Busan, Chuncheon, Daegu, Daejeon, Gangneung, Gwangju
2026-04-01
Recruiting
AbbVie
Phase 2
165
Busan, Bucheon-si, Seongnam-si, Seoul
2026-01-23
Recruiting
Contineum Therapeutics
Phase 2
324
Seoul, Bucheon-si, Seongnam-si, Songpa-dong, Incheon
2026-01-08
Not yet open
Inha University Hospital
Phase 4
1,898
Incheon, Ansan, Bucheon-si, Busan, Cheonan, Goyang, Goyang-si, Guri-si
2026-01-01
Recruiting
ROKIT Healthcare
Phase 4
104
Daegu, Bucheon-si, Guri-si, Gwangmyeong, Seongnam-si, Goyang, Incheon, Jeonju
2025-12-29
Recruiting
Jaseng Medical Foundation
Not applicable
96
Seoul, Bucheon-si, Seongnam
2025-12-17
Active, closed
Exosystems
Not applicable
130
Bucheon-si, Suwon
2025-11-28
Recruiting
UCB Biopharma SRL
Phase 3
320
Anyang-si, Bucheon-si, Busan, Gwangju, Jeonju, Seongnam-si, Seoul
2025-11-14
Recruiting
Eli Lilly and Company
Phase 3
4,500
Ansan-si, Bucheon-si, Busan, Daegu, Dongjak-gu, Guri-si, Incheon, Jinju
2025-10-15
Recruiting
Samsung Medical Center
Not applicable
3,500
Bucheon-si, Daegu, Gwangju, Gwangmyeong, Ilsan, Incheon, Jeonju, Jinju
2025-10-02
Recruiting
Eli Lilly and Company
Phase 3
1,000
Anyang-si, Bucheon-si, Busan, Gwangju, Junggu, Seoul
2025-09-30
Recruiting
Jaseng Medical Foundation
Not applicable
92
Bucheon-si, Seongnam-si, Seoul
2025-08-22
Recruiting
Gilead Sciences
Phase 1/2
200
Ansan-si, Bucheon-si, Seoul
2025-07-31
Recruiting
Myungmoon Pharma. Co. Ltd.
Phase 4
484
Ansan, Bucheon-si, Suwon, Busan, Daegu, Gyeonggi-do, Incheon, Seoul
2025-07-28
Recruiting
Jung-min Ahn
Phase 4
5,000
Anyang, Bucheon-si, Busan, Changwon, Cheonju, Chuncheon, Daegu, Daejeon
2025-07-24
Recruiting
Boehringer Ingelheim
Phase 3
11,800
Ansan-si, Bucheon-si, Busan, Daejeon, Daejoen, Gwangju, Incheon, Seongnam
2025-07-22
Recruiting
AstraZeneca
Phase 3
15,100
Bucheon-si, Busan, Changwon-si, Daegu, Daejeon, Goyang-si, Gwangju, Gwangmyeong
2025-06-04
Active, closed
AstraZeneca
Phase 3
3,103
Anyang-si, Bucheon-si, Busan, Changwon-si, Cheonan-si, Daegu, Daejeon, Gangwon-do
2025-05-28
Recruiting
AstraZeneca
Phase 3
11,300
Bucheon-si, Cheongju-si, Daegu, Seongnam-si, Seoul, Suwon, Wŏnju, Yangsan
2025-03-14
Recruiting
IRIS-Coroflex NEO Cohort
NCT06177743Coronary Artery Stenosis, Coronary Artery Disease
Seung-Jung Park
Observational
1,000
Seoul, Bucheon-si, Daegu, Gwangju, Ilsan, Sejong, Suwon, Uijeongbu-si
2025-01-09
Active, closed
AbbVie
Phase 2
83
Ansan-si, Bucheon-si, Seoul
2024-12-19
Active, closed
Sanofi Pasteur, a Sanofi Company
Phase 3
1,714
Busan, Daegu, Gwangju, Ansan-si, Anyang-si, Bucheon-si, Hwaseong-si, Seongnam-si
2024-12-18
Recruiting
Duk-Woo Park, MD
Phase 4
1,040
Bucheon-si, Changwon, Daegu, Daejeon, Gangneung, Gwangju, Ilsan, Incheon
2024-12-18
Active, closed
Vicore Pharma AB
Phase 2
378
Bucheon-si, Busan, Goyang-si, Seoul
2024-12-09
Active, closed
Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 Diabetes
NCT06712615Type 2 Diabetes Mellitus (T2DM), Obesity Type 2 Diabetes Mellitus
DrugPG-102
ProGen. Co., Ltd.
Phase 2
144
Bucheon-si, Daegu, Daejeon, Seongnam, Seoul
2024-12-05
Recruiting
Boehringer Ingelheim
Phase 3
1,590
Bucheon-si, Busan, Incheon, Seoul, Wŏnju
2024-11-12
Recruiting
Boehringer Ingelheim
Phase 3
1,800
Bucheon-si, Busan, Deagu, Incheon, Seoul, Wŏnju
2024-10-14
Active, closed
Incyte Corporation
Phase 3
349
Ansan-si, Bucheon-si, Busan, Incheon, Jeonju, Seoul
2024-10-10
Recruiting
GlaxoSmithKline
Phase 2
393
Ansan, Bucheon-si, Daegu, Seoul, Suwon Gyeonggi-do
2024-09-27
Active, closed
Takeda
Phase 3
2,099
Wŏnju, Gwangju, Beon-gil Bundang-gu, Bucheon-si, Gwangjin-Gu, Seocho-Gu, Seoul
2024-09-04
Active, closed
Starmed
Not applicable
70
Bucheon-si
2024-08-21
Recruiting
AbbVie
Phase 3
675
Ansan-si, Bucheon-si, Seoul
2024-08-19
Active, closed
Jaseng Medical Foundation
Not applicable
250
Bucheon-si, Daejeon, Haeundae, Seoul, Yangsan
2024-07-07
Active, closed
Novo Nordisk A/S
Phase 3
10,000
Bucheon-si, Goyang-si, Seongnam-si, Suwon, Yangsan, Busan, Cheongju-si, Daegu
2024-06-25
Recruiting
Boehringer Ingelheim
Phase 3
6,712
Bucheon-si, Busan, Cheongju-si, Daejeon, Deagu, Gwangju, Incheon, Seongnam
2024-06-17
Recruiting
Duk-Woo Park, MD
Not applicable
1,500
Bucheon-si, Daegu, Daejeon, Gangneung, Gwangju, Ilsan, Incheon, Pusan
2024-06-14
Recruiting
AbbVie
Phase 3
200
Ansan-si, Bucheon-si, Suwon, Seoul
2024-06-14
Recruiting
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
DrugPegozafermin
89bio, Inc.
Phase 3
762
Bucheon-si, Busan, Daegu, Incheon, Seoul
2024-05-24
Active, closed
Boehringer Ingelheim
Phase 3
1,666
Bucheon-si, Seongnam, Seoul
2024-05-06
Recruiting
Seung-Jung Park
Not applicable
960
Seoul, Ansan, Anyang, Bucheon-si, Busan, Changwon, Chuncheon, Daegu
2024-04-25
Recruiting
NEUROPHET
Not applicable
30
Bucheon-si
2024-04-22
Recruiting
AstraZeneca
Phase 3
3,850
Anyang-si, Bucheon-si, Busan, Cheongju-si, Daegu, Daejeon, Gwangju, Gwangmyeong
2024-04-12
Active, closed
Janssen Research & Development, LLC
Phase 3
731
Ansan-si, Anyang-si, Bucheon-si, Gwangju, Seongnam, Seoul
2024-03-09
Active, closed
Eli Lilly and Company
Phase 3
17,300
Bucheon-si, Daegu, Daejeon, Dongjak-gu, Gwangju, Namdong-gu, Seongnam, Seoul
2024-03-05
Recruiting
A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants
NCT06246123Arthritis, Rheumatoid, Colitis, Ulcerative
Eisai Korea Inc.
Observational
2,040
Cheonan, Chuncheon, Wŏnju, Ansan, Bucheon-si, Goyang-si, Gwangmyeong, Seongnam-si
2024-02-27
Recruiting
Neuracle Science Co., LTD.
Phase 1/2
138
Bucheon-si, Gwangju, Ilsan, Pusan, Pyeongchon, Seongnam, Seoul, Suwon
2024-01-19
Recruiting
Colorado Prevention Center
Phase 3
5,200
Gwangju, Wŏnju, Seoul, Bucheon-si, Incheon, Daejeon, Cheongju-si, Busan
2024-01-17
Active, closed
AbbVie
Phase 3
614
Daejeon, Bucheon-si, Suwon, Seoul
2023-12-19
Recruiting
Fontan Udenafil Exercise Longitudinal Assessment Trial - 2
NCT05918211Single Ventricle Heart Disease
Mezzion Pharma Co. Ltd
Phase 3
436
Bucheon-si, Seoul
2023-10-30
Active, closed
Bristol-Myers Squibb
Phase 3
1,057
Goyang-si, Jongno-gu, Songpa-gu, Yongsan-gu, Dong-gu, Bucheon-si, Bucheonsi Weonmigu, Busan
2023-10-25
Recruiting
Samsung Medical Center
Not applicable
2,000
Bucheon-si, Chuncheon, Chungju, Daegu, Daejeon, Gwangju, Gwangmyeong, Ilsan
2023-10-02
Active, closed
Bristol-Myers Squibb
Phase 3
1,255
Goyang-si, Jongno-gu, Yongsan-gu, Dong-gu, Bucheon-si, Bucheonsi Weonmigu, Busan, Gyeonggi-do
2023-09-14
Recruiting
Ipsen
Phase 3
276
Bucheon-si, Busan, Daegu, Daejeon, Goyang-si, Gyeonggi-do, Incheon, Junggu
2023-08-31
Recruiting
Jaseng Medical Foundation
Not applicable
200
Seoul, Bucheon-si, Busan, Daejeon
2023-08-09
Active, closed
Hoffmann-La Roche
Phase 3
459
Anyang-si, Bucheon-si, Cheongju-si, Gyeonggi-do, Seongnam-si, Seoul
2023-08-08
Recruiting
Asciminib RMP Study
NCT05943522Chronic Myeloid Leukemia
Novartis Pharmaceuticals
Observational
600
Wŏnju, Anyang-si, Bucheon-si, Uijeongbu-si, Gyeonggi-do, Incheon, Seoul, Suwon
2023-07-19
Active, closed
Hoffmann-La Roche
Phase 3
2,000
Bucheon-si, Daegu, Gyeonggi-do, Incheon, Jeollabuk-do, Seoul, Wŏnju
2023-06-28
Recruiting
Anterogen Co., Ltd.
Observational
104
Bucheon-si, Seoul
2023-04-25
Active, closed
Sanofi
Phase 2
999
Ansan-si, Bucheon-si, Yangsan, Incheon, Seoul
2023-04-03
By invitation
Seung-Whan Lee, M.D., Ph.D.
Phase 4
4,000
Bucheon-si, Changwon, Cheonju, Chuncheon, Daegu, Daejeon, Gangneung, Gwangju
2023-03-14
Recruiting
Seung-Whan Lee, M.D., Ph.D.
Not applicable
2,400
Anyang, Bucheon-si, Busan, Changwon, Cheongju-si, Daegu, Gangneung, Iksan
2023-03-13
Active, closed
ModernaTX, Inc.
Observational
4,207
Wŏnju, Bucheon-si, Gimpo-si, Goyang-si, Gwangmyeong, Namyangju, Siheung, Yangju
2023-03-10
Active, closed
Areteia Therapeutics
Phase 3
600
Anyang-si, Bucheon-si, Busan, Gwangju, Incheon, Jeonju, Seoul, Suwon
2023-01-30
Active, closed
Hoffmann-La Roche
Phase 3
1,290
Bucheon-si, Daegu, Gyeonggi-do, Seoul, Wŏnju
2022-12-29
Active, closed
Novo Nordisk A/S
Phase 3
3,400
Bucheon-si, Seongnam-si, Yangsan, Daegu, Daejeon, Incheon, Seongnam-si, Gyeonggi-do, Seoul
2022-11-01
Recruiting
Yonsei University
Not applicable
450
Bucheon-si, Changwon, Chungju, Seoul
2022-11-01
Recruiting
Asan Medical Center
Phase 4
3,944
Bucheon-si, Busan, Changwon, Chuncheon, Chungju, Daegu, Daejeon, Gangneung
2022-10-21
By invitation
Comparison Study Between Suction Aspiration and Combination Technique in Acute Cerebral Infarction
NCT06254755Acute Cerebral Ischemia Requiring for Mechanical Thrombectomy
Inje University Haeundae Paik Hospital
Not applicable
1,132
Goyang-si, Seongnam-si, Changwon, Bucheon-si, Daegu, Daejeon, Incheon, Pohang
2022-10-01
Active, closed
Seoul National University Bundang Hospital
Observational
1,000
Bucheon-si, Chungju, Daegu, Daejeon, Goyang, Hwasun, Incheon, Jeonju
2022-09-28
Active, closed
GlaxoSmithKline
Phase 3
3,038
Ansan, Bucheon-si, Incheon, Kangwon-do, Seoul
2022-08-10
Active, closed
Daewoong Pharmaceutical Co. LTD.
Phase 2
102
Busan, Bucheon-si, Goyang-si, Hwaseong-si, Seoul, Ulsan
2022-07-29
Recruiting
Resting Full-cycle Ratio (RFR)-Guided Revascularization
NCT06075160Coronary Artery Disease
Sejong General Hospital
Observational
1,167
Bucheon-si
2022-07-27
Active, closed
PureTech
Phase 2
240
Bucheon-si, Goyang-si, Busan, Daegu, Gwangju, Gyeonggi-do, Incheon, Seoul
2022-07-22
Active, closed
Yuhan Corporation
Observational
2,001
Chilgok, Chuncheon, Wŏnju, Bucheon-si, Uijeongbu-si, Iksan, Seoul, Busan
2022-06-24
Active, closed
Novartis Pharmaceuticals
Observational
683
Daegu, Wŏnju, Bucheon-si, Bundang Gu, Goyang-si, Yangsan, Jeonju, Suncheon
2022-05-09
Recruiting
Joon Bum Kim
Phase 4
1,300
Bucheon-si, Busan, Daegu, Gangneung, Gwangju, Seongnam, Seoul, Suwon
2022-02-21
Recruiting
Twice vs Thrice Weekly Incident Hemodialysis in Elderly Patients
NCT06141798Age Problem, Dialysis; Complications, Frailty, Quality of Life
Soonchunhyang University Hospital
Not applicable
428
Bucheon-si, Chuncheon, Seoul, Wŏnju
2021-11-23
Active, closed
Kang Stem Biotech Co., Ltd.
Observational
262
Bucheon-si
2021-10-05
Recruiting
Pharmicell Co., Ltd.
Observational
100
Ansan, Bucheon-si, Cheonan, Chuncheon, Gangneung-si, Seoul, Wŏnju, Yongin
2021-09-09
By invitation
Viatris Innovation GmbH
Phase 3
25,000
Bucheon-si, Busan, Cheongju-si, Daegu, Daejeon, Gangseo-gu, Goyang-si, Incheon
2021-08-14
By invitation
Philips Clinical & Medical Affairs Global
Not applicable
3,212
Bucheon-si, Daegu, Seoul
2021-06-17
Recruiting
Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy
NCT04416581Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome, Myocardial Infarction
Duk-Woo Park, MD
Phase 4
3,320
Anyang, Bucheon-si, Busan, Changwon, Cheonan, Cheonju, Chuncheon, Daegu
2021-05-12
Recruiting
Pharmicell Co., Ltd.
Phase 3
200
Ansan, Bucheon-si, Cheonan, Chuncheon, Gangneung-si, Seoul, Wŏnju, Yongin
2021-04-19
Active, closed
Evolocumab in STEMI
NCT06081803ST Elevation Myocardial Infarction
DrugRepatha
Sejong General Hospital
Phase 3
166
Bucheon-si
2020-12-05
Recruiting
Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI
NCT04499859Myocardial Infarction, Statin Adverse Reaction, HMG-CoA Reductase Inhibitor Toxicity
DrugsEzetimibe·Rosuvastatin
Kiyuk Chang, MD,PhD
Phase 4
3,548
Bucheon-si, Suwon, Uijeongbu-si, Daejeon, Incheon, Seoul
2020-10-01
Recruiting
Asan Medical Center
Observational
3,000
Bucheon-si, Busan, Changwon, Chuncheon, Daegu, Daejeon, Gangneung, Jeonju
2020-02-20
Active, closed
Timing of FFR-guided PCI for Non-IRA in STEMI and MVD (OPTION-STEMI)
NCT04626882Myocardial Infarction, Acute, Multi-Vessel Coronary Artery Stenosis
Chonnam National University Hospital
Not applicable
994
Bucheon-si, Changwon, Daegu, Gangneung, Gwangju, Jeonju, Jinju, Seoul
2019-12-30
Active, closed
Galderma R&D
Phase 3
1,700
Bucheon-si, Busan, Gyeonggi-do, Incheon, Seoul
2019-12-30
Active, closed
PULSTA Transcatheter Pulmonary Valve Pre-Approval Study
NCT03983512Heart Diseases, Pulmonary Valve Regurgitation, Pulmonary Valve Stenosis, Tetralogy of Fallot
Taewoong Medical Co., Ltd.
Not applicable
58
Seoul, Bucheon-si
2019-10-07
Active, closed
SyncAV Post-Market Trial
NCT04100148Congestive Heart Failure
Abbott Medical Devices
Not applicable
1,686
Bucheon-si, Daegu, Seongnam, Seoul
2019-10-03
Recruiting
Transpacific TAVR Registry
NCT03826264Heart Valve Diseases, Aortic Valve Insufficiency
Duk-Woo Park, MD
Observational
10,000
Bucheon-si, Daejeon, Seoul
2019-06-15
Active, closed
SCM Lifescience Co., LTD.
Observational
42
Bucheon-si, Daegu, Goyang-si, Gwangju, Incheon, Suwon
2019-05-10
Recruiting
Seung-Jung Park
Observational
500
Bucheon-si, Daegu, Daejeon, Gwangju, Pusan, Seongnam, Seoul
2018-09-04
Active, closed
Seung-Jung Park
Observational
900
Bucheon-si, Seoul, Yangsan
2018-05-10
Recruiting
Seung-Whan Lee, M.D., Ph.D.
Observational
4,000
Anyang, Bucheon-si, Changwon, Cheongju-si, Chuncheon, Daegu, Daejeon, Gangneung
2018-01-11
Active, closed
Gilead Sciences
Phase 3
340
Bucheon-si, Busan, Daegu, Seongnam, Seoul, Songpa-Gu
2017-12-12
Recruiting
Kee-joon Choi
Phase 4
140
Bucheon-si, Busan, Cheonan, Daegu, Daejeon, Gangneung, Gwangju, Iksan
2016-11-29
Active, closed
IRIS-Synergy Cohort in the IRIS-DES Registry
NCT02720419Coronary Artery Disease
Jung-min Ahn
Observational
3,000
Bucheon-si, Busan, Cheonan, Chuncheon, Daegu, Daejeon, Gangneung, Gwangju
2016-08
Active, closed
IRIS-Onyx Cohort in the IRIS-DES Registry
NCT02593994Coronary Artery Disease, Arterial Occlusive Diseases, Cardiovascular Diseases, Percutaneous Transluminal Angioplasty
Seung-Jung Park
Observational
4,500
Seoul, Anyang, Bucheon-si, Cheonan, Chuncheon, Daegu, Daejeon, Gangneung
2015-10
Recruiting
Drug-Eluting Balloon Registry in Routine Clinical Practice
NCT02038660Coronary Artery Disease, Angioplasty, Balloon
Seung-Jung Park
Observational
1,500
Bucheon-si, Daegu, Daejeon, Gwangju, Pusan, Seoul, Ulsan
2014-01
Recruiting
Seung-Jung Park
Observational
20,000
Anyang, Bucheon-si, Cheongju-si, Chuncheon, Daegu, Daejeon, Gangneung, Gwangju
2011-06
Recruiting
Observational Study for Left Main Disease Treatment
NCT01341327Coronary Artery Disease
Seung-Jung Park
Observational
10,000
Anyang, Bucheon-si, Busan, Cheonan, Cheongju-si, Daegu, Daejeon, Gangneung
2007-07
Rows per page Showing 1–112 of 112
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-south-korea/city/bucheon-si

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,365 studies in total at the last sync on 11 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 112 of those studies with a site in Bucheon-si.

How many clinical trials are recruiting in Bucheon-si?

60 of the 112 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:17 UTC sync. A further 7 have not yet opened recruitment, 41 are active but closed to new participants, and 4 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Bucheon-si), 112 studies
PhaseStudiesRecruitingShare
Phase 3442039.3%
Observational251522.3%
Not applicable211118.8%
Phase 41199.8%
Phase 2938%
Phase 1/2221.8%

Most active sponsors

Lead sponsors with the most studies (Bucheon-si)
Lead sponsorStudiesRecruiting
Seung-Jung Park97
AstraZeneca65
AbbVie53
Boehringer Ingelheim54
Jaseng Medical Foundation54
Duk-Woo Park, MD44
Eli Lilly and Company42
Bristol-Myers Squibb30
Hoffmann-La Roche30
Novo Nordisk A/S30
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.